Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

Interim Management Statement

22 May 2012 11:15

RNS Number : 8383D
Flying Brands Limited
22 May 2012
 



22 May 2012

 

 

FLYING BRANDS LIMITED

 

Trading Update

 

As announced on 1 May, we have now completed the disposals of our Gifts Division and of the Garden Bird Supplies, Garden Centre Online and Listen2 businesses ( together the "Sold Businesses").The business of the Group now comprises the Gardening Direct retail business, the Growing and Live Despatch business (GLD) and the freehold property at Retreat Farm. We are reporting today Group orders for the three month period to 31 March 2012 and for these purposes the Gardening Direct retail business and GLD are grouped together as the "Garden Division".

 

Overall Group Orders for the period to 31 March 2012 were £7.0m (2011: £10.8m). Orders for the Garden Division for the period were £3.8m (2011: £5.5m). Orders for the Sold Businesses for the period were £3.2 m (£5.3 m).

 

The Garden Division continues to face a number of challenges. The gardening industry generally this year has suffered as a result of a combination of poor weather and the continuing uncertain consumer outlook. In addition, we and our principal competitors have suffered as a result of the abolition of Low Value Consignment Relief earlier this year. We believe that the resulting increase in prices did have the effect of reducing demand and we, along with most of our competitors, have had to respond by reducing prices in the latter half of the season.

 

Our restructuring programme to cut central overheads, announced with our annual results on 30 April, is proceeding according to plan. We are continuing discussions with a number of prospective purchasers of our gardening businesses and will provide an update when appropriate. 

 

 

For further information, please contact:

 

Flying Brands Limited 01245 228 300

Stephen Cook, Chief Executive

Stuart Dootson, Group Finance Director

Smithfield Consultants 020 7360 4900

John Kiely

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBLLFLLEFFBBX
Date   Source Headline
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership
31st May 202211:05 amRNSSecond Price Monitoring Extn
31st May 202211:00 amRNSPrice Monitoring Extension
31st May 20228:00 amRNSSubmission of FDA 510(k) Application for IB Zero G
30th May 202210:47 amRNSResult of AGM
5th May 20223:00 pmRNSNotice of AGM
3rd May 20222:21 pmRNSIB Broadens Quantitative Mapping
28th Apr 20225:52 pmRNSFinal Results
9th Mar 20223:08 pmRNSIQAI’s Sponsored Phase I Clinical Trial is Open
28th Feb 202211:12 amRNSTotal Voting Rights
8th Feb 20227:00 amRNSIssue of shares to Mayo Clinic
27th Jan 20227:00 amRNSImaging Biometrics LLC - Letter to Shareholders
4th Jan 20229:27 amRNSDirector/PDMR Shareholding
17th Dec 20217:37 amRNSIQ-AI Prepares for Phase I Clinical Trial Launch
13th Dec 202110:32 amRNSDirector's Interest
11th Nov 20218:52 amRNSAgreement with St. Jude Children’s Hospital
2nd Nov 20218:19 amRNSMD ANDERSON ADOPTS IB CLINIC
28th Oct 20214:00 pmRNSLetter to Shareholders
7th Oct 20214:41 pmRNSSecond Price Monitoring Extn
7th Oct 20214:36 pmRNSPrice Monitoring Extension
7th Oct 20212:05 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202112:00 pmRNSPlacing
1st Oct 20218:17 amRNSCase Report on Clinical Value of IB Software
22nd Sep 20217:00 amRNSEU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
17th Sep 20217:00 amRNSIB Software Chosen for Accuracy and Automation
10th Sep 20217:00 amRNSUpdate on Phase I Clinical Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.